Femasys (NASDAQ:FEMY) Shares Down 14.6% – Here’s What Happened

Posted by Brenda Bartman on Jul 17th, 2026

Femasys Inc. (NASDAQ:FEMY – Get Free Report) was down 14.6% on Thursday . The company traded as low as $3.04 and last traded at $3.05. Approximately 43,437 shares were traded during mid-day trading, an increase of 38% from the average daily volume of 31,380 shares. The stock had previously closed at $3.57.

Wall Street Analysts Forecast Growth

FEMY has been the topic of a number of analyst reports. Wall Street Zen raised Femasys to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings raised Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 3rd. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $106.67.

View Our Latest Analysis on FEMY

Femasys Stock Performance

The stock has a fifty day simple moving average of $5.53 and a two-hundred day simple moving average of $8.67. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.98 and a current ratio of 3.91. The stock has a market cap of $9.21 million, a price-to-earnings ratio of -0.56 and a beta of -2.13.

Femasys (NASDAQ:FEMY – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $1.43. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.The company had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $0.77 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kovack Advisors Inc. acquired a new stake in shares of Femasys in the 4th quarter valued at approximately $27,000. Osaic Holdings Inc. acquired a new position in Femasys during the 2nd quarter worth approximately $45,000. HRT Financial LP acquired a new stake in Femasys in the fourth quarter valued at approximately $30,000. Cetera Investment Advisers bought a new stake in shares of Femasys during the fourth quarter worth $36,000. Finally, State Street Corp grew its stake in shares of Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after buying an additional 24,500 shares during the last quarter. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

(Get Free Report)

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.